ArticleJournal of applied oral science : revista FOB2025
A comparative study of three liquid platelet concentrates on human primary osteoblast activity: an in vitro study.
Article in Journal of applied oral science : revista FOB, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Outcome Analysis of Leukocyte-Rich Platelet-Rich Plasma, Leukocyte-Poor Platelet-Rich Plasma, and Injectable Platelet-Rich Fibrin in the Management of Chronic Plantar Fasciitis: A Prospective Comparative Study.Journal of orthopaedic case reports · 2026Article
- The efficacy of blood-derived growth factor source compared to bone-derived growth factor source on bone regeneration in critical-sized rabbit calvarial bone defects.BMC oral health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effects of concentrated platelet-rich fibrin (C-PRF), injectable platelet-rich fibrin (i-PRF), and platelet-rich plasma (PRP) on cellular activity of human primary osteoblasts. METHODOLOGY: C-PRF, i-PRF, and PRP were prepared from five donors and pre-cultured in 5 mL of culture medium for three days. Human primary osteoblasts were seeded and cultured with 20% conditioned medium derived from the three platelet concentrates. Then, osteoblast viability was assessed at 24 h; proliferation at one, three, and five days; differentiation at seven days; mineralization at 14 days; and gene expression RUNX family transcription factor 2 (RUNX2), alkaline phosphatase, biomineralization associated (ALPL), collagen type I alpha 1 chain (COL1A1), and osteocalcin (OCN) at three and 14 days were investigated.
resultsOsteoblasts cultured with C-PRF, i-PRF, and PRP demonstrated excellent biocompatibility. Proliferation was significantly higher in all platelet concentrates compared to the controls at one, three, and five days, with no significant differences among them, except on day one. Alkaline phosphatase and Alizarin Red S staining were significantly higher in the C-PRF and i-PRF groups compared to the PRP and control groups. However, RUNX2, ALPL, COL1A1, and OCN mRNA levels did not differ significantly among the three platelet concentrates throughout the study period.
conclusionOur study indicates that the three liquid platelet concentrates enhance human osteoblast activity. C-PRF and i-PRF promoted greater differentiation and mineralization than PRP. These findings show that all liquid platelet concentrates positively influence human osteoblast proliferation and differentiation, making them suitable for clinical applications requiring bone regeneration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.